Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
12
×
life sciences
national blog main
san francisco blog main
san francisco top stories
12
×
national top stories
biotech
boston blog main
boston top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
cancer
glaxosmithkline
bristol-myers squibb
fda
merck
pfizer
regeneron pharmaceuticals
roche
astrazeneca
inclisiran
novartis
What
drug
roundup
bio
cancer
cholesterol
pricing
biotech
buy
ceo
conference
days
drugs
european
hit
lowering
lung
medical
medicine
medicines
new
news
opioid
week
abbvie’s
according
aces
acquisitions
advanced
advantages
akcea
alliance
amgen
amgen’s
announced
annual
approval
arrival
ash
august
award
Language
unset
12
×
Current search:
amgen
×
unset
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More